MWMarek Wroński

Marek Wroński

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marek Wroński has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Brain-derived neurotrophic factor in gastroenterology oncology – short review of current literature

    by Tomasz Antoni Guzel, Katarzyna Mech, Marek Wroński, Katarzyna Gerkowicz, Agata Bednarczyk, Weronika Adamczyk, Monika Radecka, Maciej Słodkowski

    Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophins group which plays a crucial role in brain development and neurogenesis. In the hypothalamus it is described as playing a role in energy metabolism and feeding behaviour. The hippocampal concentration of BDNF is believed to...


  • Open Access

    Brain derived neurotrophic factor declines after complete curative resection in gastrointestinal cancer

    by Tomasz Guzel, Katarzyna Mech, Marzena Iwanowska, Marek Wroński, Maciej Słodkowski

    Background: Brain derived neurotrophic factor (BDNF) is a neurotrophin involved in neural and metabolic diseases, but it is also one of the crucial factors in cancer development and metastases. In the current study, we investigated serum BDNF concentrations in patients that underwent surgical treatment for colorectal cancer or pancreatic cancer. Methods: Serum BDNF concentrations were measured with standard enzyme-linked immunosorbent assays, before and on the third day after the operation, in 50 consecutive patients with colorectal cancer and 25 patients with pancreatic cancer (tumours in the head of pancreas). We compared pre- and postoperative BDNF levels, according to the subsequent TNM stage, histologic stage, lymph node involvement, neuro- or angio-invasion, and resection range. Results: In the pancreatic cancer group, BDNF concentrations fell significantly postoperatively (p = 0.011). In patients that underwent resections, BDNF concentrations fell (p = 0.0098), but not in patients that did not undergo resections (i.e., laparotomy alone). There were significant pre- and postoperative differences in BDNF levels among patients with (p = 0.021) and without (p = 0.034) distant metastases. Significant reductions in BDNF were observed postoperatively in patients with small tumours (i.e., below the median size; p = 0.023), in patients with negative angio- or lymphatic invasion (p = 0.028, p = 0.011, respectively), and in patients with lymph node ratios above 0.17 (p = 0.043). In the colon cancer group, the serum BDNF concentrations significantly fell postoperatively in the entire group (p = 0.0076) and in subgroups of patients with or without resections (p = 0.034, p = 0.0179, respectively). Significant before-after differences were found in subgroups with angioinvasions (p = 0.050) and in those without neuroinvasions (p = 0.049). Considering the TNM stages, the postoperative BDNF concentration fell in groups with (p = 0.0218) and without (p = 0.034) distant metastases and in patients with tumours below the median size (p = 0.018). Conclusion: Our results suggested that BDNF might play an important role in gastrointestinal cancer development. BDNF levels were correlated with tumour volume, and with neuro-, angio- and lymphatic invasions. In pancreatic cancer, BDNF concentrations varied according to the surgical procedure and they fell significantly after tumour resections. Thus, BDNF may serve as a potential marker of complete resections in underdiagnosed patients. However, this hypothesis requires further investigation. In contrast, no differences according to the procedure was made in patients with colon cancer.


  • Surgical management of the grade C pancreatic fistula after pancreatoduodenectomy

    by Marek Wroński, Włodzimierz Cebulski, Bartosz Witkowski, Tomasz Guzel, Dominika Karkocha, Gustaw Lech, Maciej Słodkowski


  • Surgical treatment of extra-appeniiceal colorectal neuroendocrine tumors

    by Jan Maryański, Agata Cyran-Chlebicka, Benedykt Szczepankiewicz, Włodzimierz Cebulski, Maciej Słodkowski, Marek Wroński

    Background: Extra-appendiceal colorectal neuroendocrine tumors are rare neoplasms with variable biological behavior. Materials and Methods: The study group consisted of 15 patients with an extra-appendiceal colorectal neuroendocrine tumor who underwent surgical resection (M/F=3:12, mean age=62.9 years). Lower-grade neuroendocrine tumors (NET G1-G2) and neuroendocrine carcinomas were recognized in 5 and 10 patients, respectively. Data were evaluated retrospectively with regard to clinical and pathologic characteristics and outcomes. Results: The median age of the patients with lower-grade NETs was significantly lower than that in patients with NECs (53 yrs vs. 68 yrs, p=0.03). NETs G1-G2 were significantly smaller than neuroendocrine carcinomas (4.0 cm vs. 6.4 cm, p=0.02). There were no differences between lower-grade NETs and NECs with regard to tumor location, local infiltration, rate of nodal involvement, and distant metastases. All the patients underwent open segmental resection of the colon or rectum. Complete resection was achieved in 3 of 5 patients from the lower-grade NET group, and ins of 10 patients in the NEC group (p=1.0). The overall survival was significantly better for lower-grade NETs tumors (p=0.005). The median survival was 4.8 months in the NEC group. The median survival in the lower-grade NET group was not achieved after a median follow-up of 69 months. Three-year overall survival was at a level of 100% for lower-grade NETs, and only 27% for NECs. Conclusion: Lower-grade neuroendocrine tumors seem to exhibit comparable potential for dissemination as neuroendocrine carcinomas, however, prognostic implications of metastases are distinct.


  • Comparison between minimally invasive and open surgical treatment in necrotizing pancreatitis

    by Marek Wroński, Włodzimierz Cebulski, Bartosz Witkowski, Mieczysław Jankowski, Andrzej Kluciński, Ireneusz W. Krasnodębski, Maciej Słodkowski


  • Right atrial tumour in a patient with acute pancreatitis

    by Agnieszka Kapłon-Cieślicka, Janusz Kochanowski, Piotr Scisło, Radosław Piątkowski, Małgorzata Kobylecka, Romuald Cichoń, Franciszek Majstrak, Włodzimierz Cebulski, Marek Wroński, Grzegorz Opolski

  • Open Access

    Walled-Off Necrosis: Safety of Watchful Waiting

    by Marek Wroński, Włodzimierz Cebulski, Waldemar Pawłowski, Ireneusz W. Krasnodębski, Maciej Słodkowski


    • 1 June 2014
      • Vol. 61  (132) , 1113-7

    Parenchyma-Sparing Pancreatic Resections: With or Without a Pancreaticojejunostomy?

    by Marek Wroński, Włodzimierz Cebulski, Ireneusz W Krasnodębski, Maciej Słodkowski

    Parenchyma-sparing pancreatic resections are used in low-grade malignant tumors, but result in a high incidence of pancreatic fistula. Pancreaticojejunostomy to the site of resection might decrease the risk of pancreatic fistula. The purpose of this study was to evaluate the influence of pancreaticojejunostomy on the outcomes of parenchyma-sparing resections. The study group consisted of 21 patients (M/F = 4:17, mean age = 47 years). Local tumor resection with a pancreaticojejunostomy was performed in 11 patients and enucleation in 10 patients. Both groups were compared retrospectively with regard to perioperative variables. The operative time was significantly shorter in the enucleation group (median 180 min vs. 222 min, P = 0.005). The overall surgical morbidity was similar in both groups (81% vs. 70%, P = 0.64). The rate of clinically significant pancreatic fistula (64% vs. 40%, P = 0.39), hemorrhagic complications (27% vs. 10%, P = 0.59) and wound infection (18% vs. 40%, P = 0.36) were comparable in both groups. One patient died after central pancreatectomy. There were no new-onset cases of diabetes mellitus postoperatively. Local resection combined with pancreaticojejunostomy is an option to avoid extensive resection of the pancreatic parenchyma, but is still associated with a high incidence of pancreatic fistula which is comparable to that after enucleation.


  • Sister Mary Joseph Nodule

    by Marek Wroński, Andrzej Kluciński, Ireneusz W. Krasnodębski

    A Sister Mary Joseph nodule represents a cutaneous metastasis into the umbilicus. This clinical sign of intra‐abdominal malignancy is frequently overlooked or misinterpreted by both patients and their physicians. We report 4 patients with a Sister Mary Joseph nodule. The umbilical metastases appeared sonographically as hypoechoic masses with irregular margins and small internal hyperechoic foci. Further evaluation revealed disseminated malignancy, and the umbilical nodule was just “a tip of an iceberg.”


  • Open Access

    Combined minimally invasive management of infected pancreatic necrosis: a case report.

    by Lukasz Wysocki, Marek Wroński, Włodzimierz Cebulski, Ireneusz Wojciech Krasnodębski

    Infected necrosis is a potentially fatal complication of necrotizing pancreatitis. Open surgical debridement is the mainstay management of infected pancreatic necrosis. Over the last decade minimally invasive techniques have been increasingly used for the treatment of infected pancreatic...